# Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia

> **NCT00795756** · PHASE2,PHASE3 · COMPLETED · sponsor: **Northern Italy Leukemia Group** · enrollment: 145 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** liposome-encapsulated cytarabine (DepoCyte)
- **DRUG:** Triple intrathecal therapy (TIT)

## Key facts

- **NCT ID:** NCT00795756
- **Lead sponsor:** Northern Italy Leukemia Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2014-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00795756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00795756, "Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00795756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*